Cancer screening of long-term cancer survivors
- PMID: 22773714
- PMCID: PMC3506256
- DOI: 10.3122/jabfm.2012.04.110118
Cancer screening of long-term cancer survivors
Abstract
Background: Although 64% of cancer survivors are expected to live at least 5 years beyond diagnosis, the receipt of cancer screening by this population is unclear. The objective of this study was to assess the relation between a cancer diagnosis and future cancer screening, exploring provider-, patient-, and cancer-specific factors that explain observed relationships.
Methods: The Wisconsin Longitudinal Study (WLS) and Wisconsin Tumor Registry were used to identify 2 participant groups: 415 patients diagnosed with nonmetastatic cancer between 1992 to 1993 (before cancer) and 2003 to 2004 (after cancer) and 4680 controls (no cancer). Adjusted average predicted probabilities of cancer screening were estimated with models that first did not include and then included, provider (provider relationship length), participant (depressive symptoms per the Center for Epidemiologic Studies Depression Scale), and cancer-specific (time since diagnosis) factors. Participants with a history of cancer associated with a given screening test were then excluded to assess whether relationships are explained by screening for recurrence versus second cancers.
Results: Female cancer survivors were more likely than no-cancer controls to undergo pelvic/Papanicolaou screening (survivors: 70%, 95% confidence interval [CI]: 63% to 76%; controls: 61%, 95% CI: 59% to 63%) and mammography screening (survivors: 86%, 95% CI: 78% to 90%; controls: 76%, 95% CI: 74% to 77%), though male cancer survivors were not more likely to receive prostate exams (survivors: 76%, 95% CI: 70% to 82%; controls: 69%, 95% CI: 67% to 71%). After excluding people with a history of the cancer being screened for, there were few significant differences in cancer screening between short- or long-term survivors (≥5 years) and no-cancer controls. Relationships were not sensitive to adjustment for provider or participant factors.
Conclusions: The significant positive differences in cancer screening between people with and without cancer can be explained by screening for recurrence. Long-term cancer survivors are not more likely to receive follow-up screening for second cancers. This information should be used by providers to ensure patients receive recommended follow-up preventive care.
Similar articles
-
Cancer screening practices among racially and ethnically diverse breast cancer survivors: results from the 2001 and 2003 California health interview survey.J Cancer Surviv. 2010 Mar;4(1):1-14. doi: 10.1007/s11764-009-0102-5. Epub 2009 Nov 2. J Cancer Surviv. 2010. PMID: 19882379
-
Cancer screening among patients with advanced cancer.JAMA. 2010 Oct 13;304(14):1584-91. doi: 10.1001/jama.2010.1449. JAMA. 2010. PMID: 20940384 Free PMC article.
-
Preventive care in prostate cancer patients: following diagnosis and for five-year survivors.J Cancer Surviv. 2011 Sep;5(3):283-91. doi: 10.1007/s11764-011-0181-y. Epub 2011 May 8. J Cancer Surviv. 2011. PMID: 21553320 Free PMC article.
-
Screening for Skin Cancer in Adults: An Updated Systematic Evidence Review for the U.S. Preventive Services Task Force [Internet].Rockville (MD): Agency for Healthcare Research and Quality (US); 2016 Jul. Report No.: 14-05210-EF-1. Rockville (MD): Agency for Healthcare Research and Quality (US); 2016 Jul. Report No.: 14-05210-EF-1. PMID: 27583318 Free Books & Documents. Review.
-
Screening for Cervical Cancer With High-Risk Human Papillomavirus Testing: A Systematic Evidence Review for the U.S. Preventive Services Task Force [Internet].Rockville (MD): Agency for Healthcare Research and Quality (US); 2018 Aug. Report No.: 17-05231-EF-1. Rockville (MD): Agency for Healthcare Research and Quality (US); 2018 Aug. Report No.: 17-05231-EF-1. PMID: 30256575 Free Books & Documents. Review.
Cited by
-
Preventative Cancer Screening Rates Among Uninsured Patients in Free Clinics: A Retrospective Cohort Study of Cancer Survivors and Non-cancer Survivors.Cancer Control. 2022 Jan-Dec;29:10732748211072983. doi: 10.1177/10732748211072983. Cancer Control. 2022. PMID: 35245986 Free PMC article.
-
Cervical Cancer Screening Among Patients with Physical Disability.J Womens Health (Larchmt). 2022 Aug;31(8):1173-1178. doi: 10.1089/jwh.2021.0447. Epub 2022 Jan 20. J Womens Health (Larchmt). 2022. PMID: 35072543 Free PMC article.
-
Trends in Participation Rates of the National Cancer Screening Program among Cancer Survivors in Korea.Cancers (Basel). 2020 Dec 30;13(1):81. doi: 10.3390/cancers13010081. Cancers (Basel). 2020. PMID: 33396692 Free PMC article.
-
Participation in breast cancer screening among breast cancer survivors -A nationwide register-based cohort study.Breast. 2020 Dec;54:31-36. doi: 10.1016/j.breast.2020.08.012. Epub 2020 Aug 30. Breast. 2020. PMID: 32898786 Free PMC article.
-
Cancer surveillance and preventive services in a diverse sample of breast and colorectal cancer survivors.J Cancer Surviv. 2021 Apr;15(2):213-223. doi: 10.1007/s11764-020-00925-4. Epub 2020 Aug 14. J Cancer Surviv. 2021. PMID: 32794009 Free PMC article.
References
-
- Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005;55(1):10–30. - PubMed
-
- Jemal A, Clegg LX, Ward E, et al. Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer. 2004;101(1):3–27. - PubMed
-
- Ganz PA. Late effects of cancer and its treatment. Semin Oncol Nurs. 2001;17(4):241–8. - PubMed
-
- Hewitt M, Greenfield S, Stovall E, editors. From Cancer Patient to Cancer Survivor: Lost in Transition. Institute of Medicine, National Research Council of the National Academies, The National Academies Press; Washington, D.C.: 2006.
-
- Khan NF, Ward A, Watson E, Austoker J, Rose PW. Long-term survivors of adult cancers and uptake of primary health services: A systematic review. Eur J Cancer. 2008;44(2):195–204. - PubMed
Publication types
MeSH terms
Grants and funding
- L K08 AG029527/AG/NIA NIH HHS/United States
- R01 AG033285-03/AG/NIA NIH HHS/United States
- UL1 TR000427/TR/NCATS NIH HHS/United States
- UL1 TR000064/TR/NCATS NIH HHS/United States
- P01 AG021079-08/AG/NIA NIH HHS/United States
- P01 AG021079/AG/NIA NIH HHS/United States
- K08 AG029527/AG/NIA NIH HHS/United States
- K08 AG029527-05/AG/NIA NIH HHS/United States
- R21 CA137288-02/CA/NCI NIH HHS/United States
- R01 AG09775/AG/NIA NIH HHS/United States
- R01 AG009775-16/AG/NIA NIH HHS/United States
- T32 HS000083-12/HS/AHRQ HHS/United States
- T32 HS000083/HS/AHRQ HHS/United States
- R21 CA137288/CA/NCI NIH HHS/United States
- P30 CA014520/CA/NCI NIH HHS/United States
- R01 AG033285/AG/NIA NIH HHS/United States
- UL1 RR025011/RR/NCRR NIH HHS/United States
- R01 AG009775/AG/NIA NIH HHS/United States
- HS000083-12/HS/AHRQ HHS/United States
- UL1 RR025011-05/RR/NCRR NIH HHS/United States
LinkOut - more resources
Full Text Sources